Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: paliperidone palmitate Clear all
Withdrawn Not applicable Interventional

Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

NCT01584466
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

NCT01193153
View directory record Official record
Conditions
Schizoaffective Disorder
Interventions
Placebo, paliperidone palmitate
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
28
States / cities
Garden Grove, California • Oakland, California • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2015 · Synced Sep 28, 2026, 9:48 PM EDT
Terminated Phase 4 Interventional Results available

Aripiprazole, Abilify Maintena Collaborative Clinical Protocol

NCT02472652
View directory record Official record
Conditions
Sexual Dysfunction
Interventions
Abilify Maintena
Drug
Lead sponsor
Gazda, Thomas D., M.D., PC
Individual
Eligibility
18 Years to 40 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bullhead City, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Not applicable Interventional Results available

A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness

NCT02085447
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Medication Adherence, Medication Non-Adherence
Interventions
CAE-L
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

NCT00535132
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Cerritos, California • Garden Grove, California • Huntington Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

NCT00488319
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
Interventions
Paliperidone ER
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
14
States / cities
Cerritos, California • San Diego, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

NCT03557931
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, placebo, risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole, brexpiprazole, paliperidone, lurasidone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease

NCT00535145
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
Interventions
Treatment as usual (TAU), Paliperidone ER
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
21
States / cities
Cerritos, California • Chino, California • Garden Grove, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Sep 28, 2026, 9:48 PM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

Study of Paliperidone ER in Adolescents and Young Adults With Autism

NCT00549562
View directory record Official record
Conditions
Autism
Interventions
Paliperidone ER
Drug
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 21 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 28, 2026, 9:48 PM EDT
Terminated Phase 4 Interventional

An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine

NCT05741502
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Clozapine, Antipsychotics,Other (non-Clozapine)
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation

NCT01134731
View directory record Official record
Conditions
Major Depressive Disorder, Suicidal Ideation
Interventions
paliperidone, lithium, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia

NCT01529515
View directory record Official record
Conditions
Schizophrenia
Interventions
PP3M 175 mg eq., PP3M 263 mg eq., PP3M 350 mg eq., PP3M 525 mg eq., Placebo (20% Intralipid emulsion)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Little Rock, Arkansas • San Fran Cisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Sep 28, 2026, 9:48 PM EDT
Not listed Phase 4 Interventional

Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning

NCT00937261
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, Paliperidone
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 60 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 3 Interventional

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

NCT00111189
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Paliperidone Palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
18
States / cities
Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 3 Interventional Results available

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

NCT00518323
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
12 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Cerritos, California • Fountain Valley, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

NCT01451736
View directory record Official record
Conditions
Schizophrenia (Recent-onset)
Interventions
paliperidone palmitate, risperidone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder

NCT00309699
View directory record Official record
Conditions
Bipolar Disorder, Mood Disorders
Interventions
Placebo, Quetiapine, Paliperidone ER
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Cerritos, California • Garden Grove, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Sep 28, 2026, 9:48 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 2 Interventional Results available

Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

NCT00632229
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Paliperidone, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
St. Petersburg, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia

NCT01559272
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone IR (Period 1), Paliperidone palmitate F015 (Panel A: treatment group 1), Paliperidone palmitate F015 (Panel A: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 1), Paliperidone palmitate F015 (Panel B: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 3), Paliperidone palmitate F015 (Panel B: treatment group 4), Paliperidone palmitate F015 (Panel B: treatment group 5), Paliperidone palmitate F016, Paliperidone palmitate F015 (Panel D: treatment group 1), Paliperidone palmitate F015 (Panel D: treatment group 2), Paliperidone palmitate F015 (Panel D: treatment group 3), Paliperidone palmitate F015 (Panel D: treatment group 4)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
10
States / cities
Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of LY03010 Compared to Listed Drug

NCT04922593
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
Interventions
LY03010; paliperidone palmitate, INVEGA SUSTENNA
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

NCT05321602
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
Interventions
LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Little Rock, Arkansas • Garden Grove, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Sep 28, 2026, 9:48 PM EDT
Completed Phase 4 Interventional Results available

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

NCT01157351
View directory record Official record
Conditions
Schizophrenia
Interventions
paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
55
States / cities
Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 28, 2026, 9:48 PM EDT